Hyloris Pharmaceuticals prepared to go publicBelgian specialty pharmaceutical company Hyloris Pharmaceuticals SA is getting ready to launch an Initial Public Offering at Euronext Brussels. more ➔
NodThera bags US$55m in Series B roundNodThera, a Scotch spin-out of Polish Selvita developing oral blockers of the NLRP3 inflammasome blockers, has filled up its cashbox with a US$55m investement. more ➔
Bacterial colonisation differs by tumour typeAn analysis of 1.500 tumours demonstrates that different human tumour types each harbour their own unique bacterial communities. more ➔
New algorithm predicts rheumatoid arthritisBased on genetic data, a new diagnostic algorithm can differentiate between five different rheumatic diseases. more ➔
Novo Holdings invests into AI CRO ExScientiaNovo Holdings leads the current US$60m Series C round of ExScientia Ltd, the world-leading artificial intelligence (AI)-driven drug discovery company. more ➔
Poxel SA raises €17.7m through capital increaseMetabolic disease specialist Poxel SA has announced a private placement of 2,358,483 new ordinary shares at €0.02 per share reserved to specified investors. more ➔
British scientists start Phase II on COVID-19 vaccineResearchers at the University Oxford and AstraZeneca have started enrolment for a Phase II/III trial to test a COVID-19 vaccine in 10,000 volunteers. more ➔
SARS-CoV2 antibody tests: not suited for individual diagnosis?An international research consortium provides data demonstrating that SARS-CoV-2 antibody tests are only useful for population-based analyses. more ➔
Vaccine to protect from any viral infectionTwo companies have presented a novel vaccination concept that might protect risk groups from new SARS-CoV-2 variants. more ➔
Abivax bags €36m fund for COVID-19 programmeFrench Abivax SA has received a €36m non-dilutive funding from Bpifrance for its ABX464 Covid-19 programme. more ➔
